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 A b s t r a c t: Objective. The aim of this study was to assess whether subclinical 
hypothyroidism (SCH) is associated with dyslipidaemia and arterial hypertension. 
 Methods. At the Department of Endocrinology, Diabetes and Metabolic Disor-
ders, Skopje, R. Macedonia, we examined 24 consecutive patients with SCH and 13 
healthy controls in a period of 6 months. SCH was defined as an elevated thyrotropin 
(TSH) (> 4.2 mU/l) and normal free thyroxine (fT4) level (10.3–24.45 pmol/l). None of 
the patients had been previously treated with thyroxine. In all participants we determi-
ned blood pressure, body mass index (BMI), TSH, fT4, antibodies to thyroid peroxidise 
(TPOabs), total lipids (TL), total cholesterol (TH), high-density lipoprotein cholesterol 
(HDL-C), low-density lipoprotein cholesterol (LDL-C), and triglycerides.  
 Results. Mean diastolic blood pressure increased in SCH patients vis-a-vis con-
trols (85 vs. 74 mmHg; p < 0.05). Mean values of TL, TH, HDL-C, LDL-C, triglyce-
rides, TC/HDL-C, and LDL-C/HDL-C were no different in patients with SCH compa-
red with controls. Individual analysis revealed that the percentages of patients with SCH 
having arterial hypertension (29%), hypertriglyceridaemia (34.78%), elevated LDL-C 
(41.66%), elevated TC/HDL-C (21.7%), and LDL-C/HDL-C (21.74%) ratios were hig-
her than the percentages in controls. No significant correlation between TSH and bio-
chemical parameters was detected.  
 Conclusion. Our study revealed that SCH patients have a greater prevalence of 
dyslipidaemia and arterial hypertension, and, as well, a greater value of mean diastolic 
pressure vs. control patients. .  
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Introduction 
 
SCH, also called mild hypothyroidism, is a term used for a condition in 
which there are small elevations in the thyroid-stimulating hormone, yet normal 
circulating levels of thyroid hormones. This condition is more common in the 
elderly and is found twice as often in women as in men [1]. In general, the pre-
valence of this condition in women ranges from 4% at age 20 to 17% at age 65 
and in men from 2% at age 20 to 7% at age 65 [2, 3]. 
Thyroid hormones have significant effects on the synthesis, mobileza-
tion and metabolism of lipids [4]. 
Overt hypothyroidism is associated with significant increases in circu-
lating concentrations of TH and LDL-C [5], but it is uncertain whether SCH is 
also associated with dyslipidaemia. Some case-control studies [6–9], but not 
others, have reported an association between SCH and dyslipidaemia in subjects 
with SCH compared with euthyroid controls. Two large cross-sectional studies 
[10, 11] reported increased serum TH, LDL-C, and triglycerides in subjects with 
SCH. By contrast several large cross-sectional studies found no significant dif-
ference in TH, LDL-C, and triglycerides between subjects with SCH and euthy-
roid subjects [12–17]. 
Whereas overt hypothyroid patients in the fifth and sixth decades of life 
have significantly higher diastolic blood pressure and arterial hypertension than 
age-matched controls, an association between arterial hypertension and SCH 
has not been reported [10, 18, 19]. 
Dyslipidaemia and arterial hypertension are risk factors for atheroscle-
rosis. The idea that overt hypothyroidism promotes atherosclerosis has been 
generally accepted, but whether SCH is associated with increased risk of athe-
rosclerosis, is still a matter of debate [20–22]. 
The study aimed to assess SCH effects on blood pressure and lipids.  
 
 
Patients and methods 
 
The study was conducted from 01.09. 2008 to 28.02. 2009, at the 
Department of Endocrinology, Diabetes and Metabolic Disorders in Skopje, R. 
Macedonia. We prospectively included 24 consecutive patients (22 female, 2 
male) with newly diagnosed SCH, defined by normal FT4 (10.3–24.45 pmol/l) 
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and elevated TSH (> 4.2 mU/l) levels. Their mean age was 45.37 ± 16.31 years 
and mean BMI was 27.67 ± 5.69 kg/m2.  
Thirteen (12 female, 1 male) healthy, euthyroid subjects were included 
in the study as a control group. Their mean age was 47.85 ± 15.78 years and 
mean BMI was 27.04 ± 4.46 kg/m2. No patients had a previous history of 
thyroid disease or took any medication related to thyroid disease or lipid meta-
bolism. Patients with diabetes mellitus, liver or renal disease, chronic pancrea-
titis, primary hyperlipidaemia, ovulatory dysfunction and infertility were exclu-
ded from the study. All patients gave informed consent to participate in the study. 
Participants had a physical examination and laboratory analyses. Out-
come measures were TSH, fT4, TPOabs, fasting TL, TH, HDL-C, LDL-C, tri-
glycerides, blood pressure, and BMI.  
Blood samples were drawn at 08:00am after a 14-hour fast. The blood 
samples for lipoproteins were analysed using Cobas Integra 700, according to 
standard methods. TH and triglycerides were determined by full enzymatic 
methods (TH-CHOD-POD-PAP and triglycerides-GPO; Cobas Integra 700, 
Hoffmann-La Roche, Basel, Switzerland). HDL-C was measured by the poly-
anion precipitation method, while LDL-C was calculated using the Friedewald 
formula. LDL-C were fractioned using ultracentrifugation in cases of triglyce-
rides exceeding 4mmol/l. Serum TSH and free T4 concentrations were measu-
red using an Immulite 2000 chemiluminescent analyser (Siemens Medical 
Solutions Diagnostics, Los Angeles, CA, USA). The sensitivity of the assays 
were 0.004 μIU/ml and 0.3 ng/dl, respectively. TPOabs was determined by 
immunometric assay obtained from Diagnostic Products Corporation (Los 
Angeles, CA). Blood pressure was measured twice in a supine position. In a 
case of hypertension (> 145/90 mmHg) the measurement was repeated after five 
minutes. The participants were weighed wearing clothes but without shoes in 
the morning with an electronic scale. Height was measured to the nearest 1 cm 
with a stadiometer. 
 
 
Statistical analysis 
 
Statistical analysis was performed using the Statistics for Windows 
programme, version 5.0. Comparison of the groups was examined using Stu-
dent’s t test. To determine the relationship between TSH and blood pressure, 
TL, TH, HDL-C, LDL-C, and triglycerides, Spearman’s non-parametric correla-
tion test was used. Spearman rank correlation was also used to determine the 
relationship between blood pressure and lipid profiles in patients with SCH. P 
values < 0.05 were considered statistically significant. 
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Results 
 
The results of the thyroid function tests and the personal characteristics 
of the two groups are shown in table 1. Eight females in the patients group and 
three females in the control group were in the post-menopausal period. Smoking 
habits were comparable in the groups. None of these females had hormone 
replacement therapy at the moment or in the previous couple of years. 
 
Table 1 – Табела 1 
  
Hormonal and personal characteristics of patients with SCH and normal controls 
Хормонални и лични каракtерисtики на pациенtиtе 
со СКХ и конtолнаtа gруpа 
 
Variables 
Subclinical 
hypothyroidism 
(n = 24) 
Controls  
(n = 13) 
df = 35 
t-value P-value 
Sex M : F 2 : 22 1 : 12 0.07 0.94(NS) 
Age (years) 45.37 ± 16.31 47.85 ± 15.78 0.45 0.66(NS) 
BMI (kg/m2) 27.67 ± 5.69 27.04 ± 4.46 0.51 0.61(NS) 
fT4 pmol/l 14.24 ± 3.38 16,21 ± 2.04 1.91 0.06(NS) 
TSH mU/L 8.86 ± 4.28 1,53 ± 0.8 6.13 < 0.0001 
Results are mean ± SD; df – degree of freedom; NS – non significant  
Резултатите се просек ± СД; Дф – степени на слобода; НС – нема сигнификантност  
 
The groups were similar with respect to sex, age and BMI (NS in all 
cases). the patients had a statistically higher TSH levels than the control group 
(p < 0.0001). Positive tests to TPOabs (> 34 iU/ml) were detected in 66.6% of 
patients and in 7.6% of controls. Patients with SCH had statistically significant 
higher diastolic blood pressure than the euthyroid, control group (85.24 ± 14.44 
vs. 74.17 ± 14.89 mmHg); (p = 0.04). Serum mean levels of TL (8.46 ± 2.15 
g/l), triglycerides (1.45 ± 0.74 mmol/l), TH (5.32 ± 1.35 mmol/l), HDL -C (1.32 
± 0.29 mmol/l), and LDL -C (3.29 ± 1.2 mmol/l) were not significantly different 
from the values in the controls (7.78 ± 1.25 g/l, 1.45 ± 0.44, 5.47 ± 1.01, 1.33 ± 
0.46, and 3.18 ± 1.02, respectively) (NS in all cases). 
The percentages of patients and controls with elevated blood pressure 
and abnormal lipid profiles are given in Table 2. The percentage of patients 
having borderline elevated triglycerides (≥ 2mmol/l), LDL-C (≥ 3.7 mmol/l), 
TH/HDL-C (> 5. 51) and LDL-C/HDL-C ratios (> 3.46) was significantly hig-
her than in the controls (p < 0.05). Hypercholesterolaemia was detected in simi-
lar percentages in patients and controls. 
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Table 2 – Табела 2 
  
Individual percentage analysis of lipid and blood pressure values of patients with SCH 
and normal controls 
Индивидуални pроценtуални анализи на лиpидниоt pрофил и крвниоt pриtисок 
кај СКХ и конtролнаtа gруpа 
 
Variables Subclinical hypothyroidism Controls 
Total lipids (≥ 10g/l) 36.84% 12.5% 
Triglycerides (≥ 2mmol/l) 34.78%   7.7% 
Total cholesterol (≥ 5.2mmol/l) 47.82%   46.15% 
LDL-C (≥ 3.7mmol/l) 41.66%           25% 
Total cholesterol/HDL-C (> 5.51) 21.74%    7.7% 
LDL-C/HDL-C (> 3.46) 21.7%             0% 
A. Hypertension ≥ 140/90mmHg 29%   15.3% 
 
A significant positive correlation was observed between blood pressure 
and TH. Serum triglyceride levels were positively correlated with TH and nega-
tively correlated with HDL-C (Table 3). In patients with SCH, no significant 
correlations were observed between TSH and TH, TL, triglycerides, LDL-C, 
HDL-C and blood pressure.  
 
Table 3 – Табела 3  
 
Spearman correlation coefficient between blood pressure 
and lipid profiles in patients with SCH 
Коефициенt на Сpерманова ранg корелација pомеѓу крвниоt pриtисок 
и лиpидниоt pрофил кај исpиtанициtе со СКХ 
 
Systolic blood 
pressure 
Diastolic blood 
pressure Triglycerides Parameter 
R p R p R P 
Total 
cholesterol 0.48 0.01 0.36 0.04 0.57 0.003 
LDL-C 0.38 0.06 0.24 0.25 0.35 0.09 
HDL-C 0.07 0.75 -0.01 0.97 -0.58 0.003 
Triglycerides 0.29 0.16 0.38 0.06 1.00 0.01 
 
  
Discussion 
 
In the present study we have demonstrated non-significant differences 
between lipid profiles in patients with SCH and values observed in age-matched 
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euthyroid controls. However, a significant percentage of these patients had arte-
rial hypertension, hypertrigliceridaemia, elevated LDL-C, elevated TH/HDL-C 
ratio, and elevated LDL-C/HDL-C ratio as compared with the control group.  
Also, we have demonstrated that patients with SCH have significantly 
higher diastolic blood pressure than the control group. We found that appro-
ximately 29% of SCH patients had diastolic hypertension compared with 15.3% 
in the euthyroid, control group. Luboshitzky et al. [9] have shown that women 
with SCH have a mean diastolic blood pressure higher than control group. This 
corresponds with our findings. Several studies have reported impaired left ven-
tricular diastolic and systolic myocardial functions in subclinical hypothyroi-
disms which reverted to normal during L-thyroxine replacement therapy [23–
25]. Exposure of aortic endothelial and vascular smooth muscle cells to triio-
dothyronine (T3) resulted in cellular relaxation. Two binding sites specific for 
T3 were identified. When cells were exposed to T3, no effect on phosphory-
lation or nitric oxide production were observed, suggesting that T3 acted di-
rectly on the vascular smooth muscle cells to cause vascular relaxation [26]. 
These data provide our results with a greater physiologic impact and rationale 
for replacement therapy. 
Results of serum lipid concentrations in SCH revealed conflicting data. 
TH and HDL-C were elevated in several reports, but were not different from 
those in the controls in most studies [7, 27]. Lower serum HDL-C levels were 
reported in few studies and were not different from the euthyroid controls in 
most other studies [7, 28]. Since LDL-C is atherogenic while HDL-C is protec-
tive, elevated TH/HDL and LDL/HDL ratios have been used as indexes of 
increased risk for atherosclerosis. In our study we found that the percentages of 
patients with atherogenic lipid profiles (TH/HDL-C and LDL-C/HDL-C) were 
higher than in the controls. 
Maas et al. [29] have demonstrated the effect of LDL-C on increased 
atherogenesis in SCH. SCH-related mechanisms, including lipid alteration, have 
not been exactly established. The cause of these alterations may be increased 
cholesterol synthesis and decreased activity of hepatic and lipoprotein lipases in 
thyroid failure [30]. Additionally, decreased cholesterol excretion, a reduced 
number of LDL receptors on the liver cell surface and decreased plasma LDL 
receptors are possible mechanisms leading to lipid abnormalities in hypothy-
roidism [31]. 
There is a growing body of evidence indicating that elevated triglyce-
ride levels are an independent risk factor for atherosclerosis [32]. Hypertriglyce-
ridaemic patients often develop a lipoprotein profile characterized by elevated 
triglycerides and LDL-C and low HDL-C [33, 34]. It is estimated that the aggre-
gated risk associated with triglycerides greater than 2.28nmol/L and a TH/ 
HDL-C ratio greater than 5.0 contributes 25% of the cardiovascular events [35]. 
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Although TSH has been suggested as the major factor in the rela-
tionship between lipid abnormalities and SCH, we did not observe any corre-
lations between lipid profiles and blood pressure on the one hand and TSH le-
vels in patients with SCH on the other [20]. The only explanation is probably 
the small sample of participants. 
 
 
Conclusion 
 
Our study revealed that SCH patients do have a greater prevalence of 
dyslipidaemia and arterial hypertension, and, as well, a greater value of mean 
diastolic pressure vs. control patients. This may increase the risk of accelerated 
atherosclerosis and premature artery disease in some patients that should be 
investigated in larger longitudinal studies. 
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 Цел: Да откриеме дали субклиничкиот хипотироидизам е асоциран со 
дислипидемија и хипертензија. 
 Маtеријали и меtоди: Спроведовме проспективна, контролирана студија на 
Клиниката за ендокринологија – Скопје, во период од 6 месеци. Во студијата 
учествуваа 24 консекутивни лица со СКХ и 13 здрави, еутироидни лица, како кон-
тролна група. СКХ беше дефиниран како зголемено ниво на тиреостимулирачки 
хормон (TSH) (> 4,2 mU/l) и нормално ниво на слободен тироксин (fT4) (10,3–
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24,45 pmol/l). Ниту еден од учесниците, претходно не беше лекуван со тироксин. 
На сите учесници им се измери крвен притисок, BMI (индекс на телесна маса), 
TSH, fT4, антитела против тироидната пероксидаза, вкупни липиди, вкупен холес-
терол, HDL, LDL холестерол и триглицериди. 
 Резулtаtи: Просечниот дијастолен крвен притисок беше зголемен кај 
пациентите со субклинички хипотироизам наспроти контолната група (85 наспро-
ти 74 mmHg; p < 0,05). Просечните вредности на вкупните липиди, триглицериди, 
вкупен холестерол, HDL холестерол и LDL холестерол не се разликуваат кај па-
циентите со СКХ во споредба со контролната група. Индивидуалните анализи 
открија дека процентот на пациентите со СКХ кои имаат хипертензија (29%), 
хипертриглицеридемија (34,78%), зголемен LDL холестерол (41,66%), вкупен хо-
лестерол/HDL (21,74%) и LDL/HDL однос (21,7%) се повисоки во однос на истиот 
процент кај контролната група. Не беше утврдена сигнификантна корелација по-
меѓу TSH и испитуваните параметри. 
 Заклучок: Нашата студија откри дека пациентите со СХ имаат поголема 
преваленца на дислипидемија и хипертензија, како и повисок просечен дијастолен 
крвен притисок  во споредба со контролната група. 
 
Клучни зборови: субклинички хипотироидизам, дислипидемија, хипертензија, 
атеросклероза, ризик фактори. 
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